Classen Immunotherapies’ Peer Reviewed Data Suggests the Measles/Mumps/Rubella Vaccine Protects Against COVID-19, Additional Studies in Progress

BALTIMORE – 05-19-2020 ( — Classen Immunotherapies Inc. has just published in the peer reviewed journal Diabetes & its Complications  evidence that the measles/mumps/rubella vaccine  may provide protection against infections with COVID-19. Non peer reviewed data from several other groups support this finding. These findings are not meant to be a clinical recommendation.  

US military has stated that the COVID-19 pandemic may be an bioweapon attack. Several respected scientist have claimed that the  genome of COVID-19 actually supports that the virus is man made. In the current publication the author explores the possibility that the COVID-19 pandemic may be a bioweapon attack. “The first step to resolve the pandemic must be to determine if the COVID-19 pandemic is a biological weapons attack”   Classen states.  To learn more about the research of immunologist J. Bart Classen, MD  see the website For further information contact  [email protected]

Media Contacts:

Company Name: Classen Immunotherapies, Inc
Full Name: . Bart Classen, MD
Email Address: Send Email

For the original news story, please visit